University of Iowa
Iowa City, Iowa, 52242, United States
Location status: Recruiting
NCT Number: NCT05937841
Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during the preeclamptic pregnancy and persists postpartum, despite the remission of clinical symptoms. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage caused by reduced endothelial function in women who have had preeclampsia compared to women who had a healthy pregnancy. Identification of these mechanisms and treatment strategies may lead to better clinical management of cardiovascular disease risk in these women.
The purpose of this study is to examine the microvascular differences in women who have had preeclampsia following activation of protective angiotensin receptors in the skin. This will help increase understanding of the mechanisms of angiotensin II receptors in these women, and how activation of these receptors may restore microvascular function.
In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) the investigators examine the blood vessels in a dime-sized area of the skin.
Interested in participating?
Request Info18 year–45 year
Female
Interventional
Early Phase 1
Iowa City, Iowa, 52242, United States
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
AT2R sensitivity: compound 21, and compound 21+ L-NAME (nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess AT2R-mediated dilation and role of nitric oxide in this response
Local heating: compound 21 is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response
Time frame: post 1 hour of skin perfusion
Cutaneous vascular vasodilator response (cutaneous conductance; %max) to exogenous compound 21 perfusion; intradermal microdialysis for the local delivery of compound 21
Time frame: post 1 hour of skin perfusion
Cutaneous vascular vasodilator response (cutaneous conductance; %max) to local heating of the skin; intradermal microdialysis for the local delivery of compound 21 compared to control (Ringer's solution), followed by L-NAME infusion to quantify NO-dependent response
Time frame: a total of 1 time during the study, within ~4 weeks following enrollment
Quantify expression of angiotensin II receptor expression in biopsied endothelial cells
Contact information is provided by the study sponsor or research team.
Anna Stanhewicz, PhD
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04479072
Cardiovascular Diseases, Female Urogenital Diseases and Pregnancy Complications
Chicago, Illinois, United States
View Trial DetailsNCT06749418
Female Urogenital Diseases and Pregnancy Complications, Hypertension, Pregnancy-Induced
Iowa City, Iowa, United States
View Trial DetailsNCT03667326
Preeclampsia Postpartum
New York, United States
View Trial DetailsNCT05924971
Female Urogenital Diseases and Pregnancy Complications, Hypertension, Pregnancy-Induced
Long Beach, California, United States
View Trial Details